Fusen Pharmaceutical Stock code:1652.HK
Company News

Fusen pharmaceutical: metformin hydrochloride sustained release tablets passed the consistency evaluation

Fusen pharmaceutical metformin hydrochloride sustained-release tablets have successfully passed the evaluation of the consistency of quality and efficacy of generic drugs! Metformin Hydrochloride Sustained Release Tablets, a diabetes drug, has been approved by the State Administration for drug control. This product has successfully passed the quality and efficacy consistency evaluation of generic drugs, which is an authoritative recognition of the R & D capacity, production and quality management system and clinical efficacy of Fusen pharmaceutical, further highlights the product brand of Fusen pharmaceutical, helps to improve the market competitiveness of the drug, and accumulates valuable experience for the company's follow-up products to carry out generic drug consistency evaluation. ▲ notice of approval from the State Drug Administration Metformin Hydrochloride Tablets is the basic medicine for diabetes. It is used for diet and physical exercise to control type 2 diabetes patients with blood glucose inefficacy, especially obesity and hyperinsulinemia. As a first-line drug for the treatment of type II diabetes, metformin is often used in combination with other oral hypoglycemic agents. ▲ for medical professionals only Because of the superiority of metformin, it is listed as the first-line treatment for hypoglycemic treatment in the guidelines for prevention and treatment of type II diabetes, formulated by professional academic organizations both at home and abroad. As the holder of drug marketing license, Fusen pharmaceutical will not forget its original intention, forge ahead, strictly control the product quality, and constantly optimize the product layout, so that more drugs of Fusen pharmaceutical can benefit the majority of patients.
26 2022.04

Jiaheng pharmaceutical was approved to set up a post doctoral research workstation sub station

Recently, the Department of human resources and social security of Guangdong Province issued a notice that the National Postdoctoral Management Committee approved Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of Fusen pharmaceutical, to set up a postdoctoral scientific research workstation branch. ▲ exhibition hall of Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd ▲ exhibition hall of Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd. is a research and development subsidiary established by Fusen pharmaceutical in response to the national development strategy of traditional Chinese medicine. In order to enhance the independent research and development ability of traditional Chinese medicine, take the research and development of high-quality and effective traditional Chinese medicine as the main goal, and integrate the high-quality traditional Chinese medicine resources in the industry. ▲ Guangdong Macao science and Technology Industrial Park of traditional Chinese Medicine The company is located in Hengqin Guangdong Macao cooperative traditional Chinese medicine science and Technology Industrial Park. It is the first R & D platform settled in the industrial park and officially operated after the establishment of Hengqin Guangdong Macao deep cooperation zone. It is the supporting unit of the large variety cultivation sub center of traditional Chinese medicine of the national traditional Chinese medicine modernization engineering technology center. Its main business is the R & D of innovative traditional Chinese medicine and secondary development of traditional Chinese medicine, chemical medicine raw materials and preparations, light medicine and beauty products and great health products. This time, Jiaheng pharmaceutical was approved to set up a post doctoral research workstation sub station, which is an affirmation of Jiaheng pharmaceutical's technological innovation ability and R & D ability, creates conditions for the company's talent training and the improvement of technological innovation ability, is conducive to further promoting the company's cooperation with universities and scientific research institutes, is conducive to the introduction of high-end R & D talents, is conducive to further improving the company's independent R & D ability and realizing the landing and transformation of scientific research achievements, Promote the sustainable innovation and development of the company and continuously improve the core competitiveness of the company.
19 2022.04

Fusen is "affectionate" and keeps "Shanghai" together | Fusen pharmaceutical donated more than 1.3 million yuan of Shuanghuanglian oral liquid and Qingre Jiedu oral liquid to support the front line of anti epidemic in Shanghai

Recently, the situation of COVID-19's prevention and control in Shanghai is grim, and the city's war epidemic is facing a tough test. In order to support Shanghai in overcoming the epidemic, giving love and giving back to the society, Fusen pharmaceutical, together with the Hong Kong young student power foundation, contacted the Shanghai Red Cross disaster preparedness and relief center, urgently allocated resources and donated drugs to the shelter of Shanghai Urban Footprint Museum and the shelter of Shanghai New International Expo Center. At present, all these equipment and materials have been sent out and are expected to arrive in Shanghai in the near future. Fusen pharmaceutical donation preparation (▲ Fusen pharmaceutical staff prepare anti epidemic materials) Shanghai aid materials ▲ materials from Fusen pharmaceutical to Shanghai Shuanghuanglian oral liquid ▲ materials from Fusen pharmaceutical to Shanghai Qingre Jiedu oral liquid Fusen Shuanghuanglian oral liquid is the first choice for the treatment of colds. At the same time, it has antibacterial and antiviral effects. It is also a family standing drug. It has been listed in the national catalogue of essential drugs and the national catalogue of medical insurance for many times. Over the past two years, Shuanghuanglian oral liquid has been listed as the recommended drug for prevention and treatment of pneumonia in New Coronavirus, Henan, Guangdong, Heilongjiang, Shaanxi and Beijing provinces. It has been widely used in epidemic prevention and control, and has made important contributions to fight against the epidemic situation. In April 2, 2022, covid-19, sponsored by the Chinese Academy of Chinese medicine, the Chinese Academy of Chinese medicine emergency branch, the Chinese Lung Association Branch of the Chinese Medicine Association and the Chinese Academy of Chinese medicine paediatric branch held the "new crown pneumonia epidemic prevention and control expert forum". Professor Wang Daowen of Tongji Medical College Affiliated to Huazhong University of Science and Technology pointed out that Shuanghuanglian oral liquid can improve the negative conversion efficiency of SARS-CoV-2 nucleic acid detection, and obviously promote mild. The absorption of inflammatory foci of pneumonia in patients with moderate and severe cov-19, combined with the standard treatment of covid-19, can enhance the antiviral effect, providing direct evidence-based medical evidence for the effectiveness and safety of covid-19 treatment. Fusen Qingre Jiedu oral liquid has the functions of antipyretic, bacteriostatic, anti-inflammatory, anti-virus and improving immunity. It is clinically used for fever, red face, irritability and thirst, sore throat caused by excessive heat toxin; Influenza and upper respiratory tract infection with the above symptoms. Shanghai aid team, let's go ▲ all donated materials of Fusen pharmaceutical have been fully packed. Go to Shanghai for support Share the robe with your son and keep "Shanghai" safe In the next few days, Fusen pharmaceutical will also Continue to pay attention to the situation of epidemic prevention and control in Shanghai Make every effort to provide support for the front line of anti epidemic The vicissitudes of the sea show their true colors, and see their original heart in times of crisis. Over the years, Fusen group has been keen on social public welfare undertakings, actively practicing social responsibility and returning the society with true feelings. It has successively donated more than 90 million yuan to the society, demonstrating the responsibility of the enterprise and the feelings of home and country with practical actions.
19 2022.04

Good news! Fusen pharmaceutical is listed as "top 50 Nanyang enterprises in 2021"!

On November 9, Nanyang Enterprise Federation and Entrepreneur Association released the list of "top 50 Nanyang enterprises in 2021" and the list of top 30 Nanyang high growth enterprises in 2021. Henan Fusen Industrial Group Co., Ltd. was listed as "top 50 Nanyang enterprises in 2021".
10 2021.11

Facing the future, Fussen Pharmaceutical Co., Ltd. is striving to revitalize national medicine as its mission

Henan Fusen Pharmaceutical Co., Ltd. was listed on the main board of the Hong Kong Stock Exchange in 2018 with stock code: 1652.HK. It is a modern comprehensive pharmaceutical company integrating medicinal plant cultivation, drug research and development, production and operation. Since its establishment in 2003, the company has been adhering to the concept of "honesty and trustworthiness, solid foundation, brand wins, and steady development", adheres to the road of "quality, technology and talents", and constantly improves the industrial chain and optimizes Internal and external resources, successively controlled the pharmaceutical research and development company Beijing Sanye Mingming Pharmaceutical Technology Co., Ltd. and the pharmaceutical distribution company Jiangxi Yongfeng Kangde Pharmaceutical Co., Ltd., and formed strategic alliances with China Resources Pharmaceutical Business Group and Jointown Pharmaceutical Group to form production, research and development, The three major areas of sales have a good development trend of "troika and synergy". It has successively won the titles of the National "Agricultural Industrialization Leading Enterprise" and Henan Province "Excellent Private Enterprise", "High-tech Enterprise", "Hundred High Enterprise" and Nanyang City's Backbone Enterprise and Top Ten Enterprise. Ingenuity quality, perfection. The company has always adhered to the pharmaceutical concept of "survive by quality". With the help of the rich resources of Chinese medicinal materials in the Funiu Mountain of 800 miles and the advantages of the first-class water quality resources in the Danjiang Reservoir of the South-to-North Water Diversion, the company has established a GAP planting base for Chinese medicinal materials to ensure product quality from the source. In strict accordance with the requirements of the national GMP production standards, we continuously optimize the production process, strictly control the process, and use ingenuity to cast drugs that "make people feel at ease". The company's existing product treatment areas cover heat-clearing and detoxifying products, cardiovascular and cerebrovascular products, blood pressure and blood sugar reduction, tonic, qi regulation, anti-anemia, antibacterial and anti-inflammatory products, among which heat-clearing products Shuanghuanglian Oral Liquid, Shuanghuanglian Injection The sales volume of liquid sheet products ranks among the top three of similar products in the country for many consecutive years. They are "National Conformity Assessment and Quality Reliable Products" and "High Quality Products in Henan Province"; Cardiovascular and cerebrovascular products, Flunarizine Hydrochloride Capsules, are the first imitation products in the country. , Ranking first in the domestic sales of similar products for five consecutive years; three exclusive varieties of Qi-regulating products Yuanhu Zhitong Oral Liquid, Ganweikang Tablets and Cardio-Cerebrovascular Products Yixinkang Tablets have been included in the national protection of traditional Chinese medicine. Technology is the foundation, innovation is the soul. The company always stands at the forefront of medical technology, adheres to the innovative development strategy, implements the policy of "integration of Chinese and Western, combination of long and short, and combination of imitation and innovation", and takes the road of new drug development of "generation of production, generation of reserves, generation of research and innovation", and research and development Innovation is the strategic basis for the high-quality development of the company. Fussen (Shenzhen) Biomedical R&D Co., Ltd. and Fussen (Macau) Co., Ltd. have been established successively, as R&D centers in the field of improved and innovative drugs, and continue to strengthen R&D capabilities and broaden product portfolios. To create a "health industry group integrating medicine, chemical medicine and biopharmaceuticals". Under the background of healthy China, the company will adhere to the corporate philosophy of "ingenuity quality • health is a blessing", taking science and technology as the forerunner, based on the traditional Chinese medicine industry, absorbing modern technology, and casting a healthy character, determined to create a century-old Fussen, a century-old brand, and Contribute to the development of the national pharmaceutical industry.
26 2021.08
Previous page



Copyright © 2021 Fusen Pharmaceutical Company Limited

豫ICP备2021028871号  Powered by

Copyright © 2021 Fusen Pharmaceutical  All Rights Reserved.      豫ICP备2021028871号        Powered by